Special Issue "hiPSC-Derived Cells as Models for Drug Discovery"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 December 2020.
Interests: reprogramming; differentiation; Brain Blood Barrier (BBB); iPSC; drug discovery; disease in a dish model
More than 85% of pre-clinically tested drugs, fail during clinical trials, which results in a long and inefficient and costly process, suggesting that animal models are often poor predictors of human biology. The ability to perform research on human is limited by the lack of physiologically relevant cells (especially the development and assessment of human brain cells and human heart cells). Currently, there are technologies to reprogram adult, somatic cells (e.g. skin biopsy, blood cells, etc) back into a pluripotent stage, termed induced pluripotent stem cells (iPSCs), and to differentiate pluripotent cells in vitro into many cell types of the body like heart, muscle, brain cells, etc. These capabilities opened a new era in human disease modeling.
For this Special Issue, we would like to invite papers that follow this concept: To use iPSC-derived cells (cardiomyocytes, fibroblasts, glial cells, neurons, astrocytes, brain microvascular endothelial cells and more) as disease models to screen leads for drugs.
Suggest models like, but not limited to:
- A blood-brain-barrier (BBB) model composed of iPSC-derived neurons, astrocytes and brain microvascular endothelial cells (iBMECs) to predict if drugs penetrate or damage the BBB.
- Neuro-regeneration vs neurodegeneration: hiPSC-derived neurological disease models, models for Traumatic Brain Injury (TBI), to suggest compounds that will follow the concept of inducing Neuro-regeneration instead of inhibiting neuro-degeneration.
- hiPSC-derived sensory cells for identifying pain relievers
- hiPSC-derived microglia cells for treating neurological diseases, and more
Suggest methodologies for monitoring drug effects in iPSC-derived disease models:
e.g. Following screening compounds, iPSC-derived neural cells will be tested for differentiation potential, proliferation and viability by quantification of protein expression, such as βIII-tubulin for neurons and GFAP for astrocytes. To assess functionality of the cells following drug exposure, Microelectrode arrays (MEA) recording for measuring excitability of neuronal cells and cellular permeability and resistance of iBMECs will be monitored.
Dr. Rivka Ofir
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- human disease models
- drug discovery
- glia cells
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Author: Rebecca Matsas
Title: Patient-derived induced pluripotent stem cell-based models in Parkinson's disease for drug identification
Author: Andreas Hermann
Title: hiPSC-derived motor neurons
Author: Vincent van Duinen
Title: A microfluidic 3D drug screening platform for anti-angiogenic compounds on iPSC derived endothelial cells